IDH1 and central nervous system cancer: Moreover, the current Phase 1/2 study evaluated the safety, efficacy, PK, and PD of Olutasidenib (FT-2102, which is a selective potent inhibitor of IDH1) as a single agent and in combination with other anticancer drugs in patients with advanced solid tumors and gliomas (43).